$ONMD
OneMedNet Corp Stock $onmd

$onmd Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224014092 Filed on April 09, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$227.0K	$1.022M	$1.022M
YoY Change
Cost Of Revenue	$329.0K	$1.150M	$1.150M
YoY Change	43.04%		-24.04%
Gross Profit	-$102.0K	-$127.9K	-$127.9K
YoY Change	78.95%		-64.54%
Gross Profit Margin	-44.93%	-12.52%	-12.52%
Selling, General & Admin	$1.969M	$6.286M	$6.388M
YoY Change	4822.5%	11814.71%	3007.84%
% of Gross Profit
Research & Development	$383.0K	$1.632M	$1.632M
YoY Change	-33.85%		71.26%
% of Gross Profit
Depreciation & Amortization		$7.980K	$27.98K
YoY Change			12.78%
% of Gross Profit
Operating Expenses	$2.352M	$6.689M	$8.246M
YoY Change	711.03%	97.62%	55.32%
Operating Profit	-$2.454M	-$6.817M	-$8.374M
YoY Change	759.68%		57.73%
Interest Expense	$15.00K	-$1.852M	-$749.2K
YoY Change	-95.59%	-412.78%	-154.62%
% of Operating Profit
Other Income/Expense, Net	-$1.135M	-$3.335M	-$3.578M
YoY Change		-1460.16%	-179.7%
Pretax Income		-$22.51M	-$23.21M
YoY Change		783.56%	-4307.64%
Income Tax		-$210.0K	$0.00
% Of Pretax Income
Net Earnings	-$3.600M	-$22.30M	-$23.21M
YoY Change	69694.49%	739.68%	-6992.89%
Net Earnings / Revenue	-1585.9%	-2182.53%	-2271.37%
Basic Earnings Per Share	-$0.15		-$0.98
Diluted Earnings Per Share	-$0.15	-$0.95	-$0.98
COMMON SHARES
Basic Shares Outstanding	23.85M shares	32.26M shares	23.57M shares
Diluted Shares Outstanding	23.94M shares		23.57M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments		$47.01K	$47.01K
YoY Change		52.28%	52.28%
Cash & Equivalents	$407.0K	$47.01K
Short-Term Investments
Other Short-Term Assets		$165.5K	$165.5K
YoY Change
Inventory
Prepaid Expenses
Receivables	$75.00K	$151.6K	$151.6K
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$956.0K	$364.2K	$364.2K
YoY Change	27706.86%	1079.75%	1079.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$85.00K	$98.87K	$98.87K
YoY Change		18.98%	18.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$85.00K	$98.87K	$98.87K
YoY Change	-99.72%	-99.66%	-99.66%
TOTAL ASSETS
Total Short-Term Assets	$956.0K	$364.2K	$364.2K
Total Long-Term Assets	$85.00K	$98.87K	$98.87K
Total Assets	$1.041M	$463.1K	$463.1K
YoY Change	-96.53%	-98.41%	-98.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$4.184M	$4.184M
YoY Change			48.67%
Accrued Expenses		$113.4K	$113.4K
YoY Change		-93.52%	-93.52%
Deferred Revenue
YoY Change
Short-Term Debt		$1.589M	$1.589M
YoY Change		13715.13%	13715.13%
Long-Term Debt Due		$44.67K	$44.67K
YoY Change
Total Short-Term Liabilities	$20.05M	$12.83M	$12.83M
YoY Change	858.77%	549.4%	549.4%
LONG-TERM LIABILITIES
Long-Term Debt		$465.0K	$465.0K
YoY Change		-83.11%	-83.11%
Other Long-Term Liabilities	$22.00K	$24.58K	$24.58K
YoY Change	-99.33%	-99.44%	-99.44%
Total Long-Term Liabilities	$22.00K	$489.6K	$489.6K
YoY Change	-99.33%	-93.14%	-93.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.05M	$12.83M	$12.83M
Total Long-Term Liabilities	$22.00K	$489.6K	$489.6K
Total Liabilities	$20.23M	$13.32M	$13.32M
YoY Change	99.69%	46.14%	46.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$97.10M	-$55.08M
YoY Change	728.22%	373.51%
Common Stock	$2.000K	$2.357K
YoY Change		418.02%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$19.19M	-$12.86M	-$12.86M
YoY Change
Total Liabilities & Shareholders Equity	$1.041M	$463.1K	$463.1K
YoY Change	-96.53%	-98.41%	-98.41%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$3.600M	-$22.30M	-$23.21M
YoY Change	69694.49%	739.68%	-6992.89%
Depreciation, Depletion And Amortization		$7.980K	$27.98K
YoY Change			12.78%
Cash From Operating Activities		$12.93M	$8.221M
YoY Change		-9084.79%	-974.13%
INVESTING ACTIVITIES
Capital Expenditures		$13.76K	$43.76K
YoY Change			-24.73%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$13.76K	-$43.76K
YoY Change		-93.54%	-98.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$29.09M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-13.51M	-8.432M
YoY Change		-8935.91%	-405.01%
NET CHANGE
Cash From Operating Activities		12.93M	8.221M
Cash From Investing Activities		-13.76K	-43.76K
Cash From Financing Activities		-13.51M	-8.432M
Net Change In Cash		-594.7K	-254.7K
YoY Change		191.46%	-39.68%
FREE CASH FLOW
Cash From Operating Activities		$12.93M	$8.221M
Capital Expenditures		$13.76K	$43.76K
Free Cash Flow		$12.92M	$8.177M
YoY Change			-918.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent		usd
CY2022Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent		usd
CY2022Q4	ONMT	Loan Extensions Current LoanExtensionsCurrent		usd
CY2022Q4	us-gaap	Loans Payable LoansPayable		usd
CY2023Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent		usd
CY2023Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent		usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent		usd
CY2022Q4	ONMT	Deferred Underwriter Fee Payable Current DeferredUnderwriterFeePayableCurrent		usd
CY2023Q4	ONMT	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent		usd
CY2023Q4	ONMT	Working Capital Loan WorkingCapitalLoan		usd
CY2023Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	ONMT	Unrealized Gain Loss UnrealizedGainLoss		usd
CY2022	ONMT	Business Combination Cost BusinessCombinationCost		usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
CY2023	ONMT	Proceeds From Issuance Of Common Stock One ProceedsFromIssuanceOfCommonStockOne		usd
CY2022	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2022	ONMT	Proceeds From Deferred Underwriting Fee ProceedsFromDeferredUnderwritingFee		usd
CY2022	ONMT	Proceeds From Issuance Of Common Stock Two ProceedsFromIssuanceOfCommonStockTwo		usd
CY2022	ONMT	Class B Common Stock ClassBCommonStock		usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40386
CY2023	dei	Entity Registrant Name EntityRegistrantName	ONEMEDNET CORPORATION
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-2076743
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	6385 Old Shady Oak Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Eden Prairie
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MN
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	55344
CY2023	dei	City Area Code CityAreaCode	800
CY2023	dei	Local Phone Number LocalPhoneNumber	918-7189
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Entity Shell Company EntityShellCompany	true
CY2024Q2	dei	Entity Public Float EntityPublicFloat	88480	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23850010	shares
CY2023	dei	Auditor Firm AuditorFirmId	5041
CY2023	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2023	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47008	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	301730	usd
CY2022Q4	us-gaap	Assets Held In Trust Current AssetsHeldInTrustCurrent	29029415	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	151640	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18975	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	165538	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	100945	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	900152	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	364186	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	30351217	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98871	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83097	usd
CY2023Q4	us-gaap	Assets Assets	463057	usd
CY2022Q4	us-gaap	Assets Assets	30434314	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4184398	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2814570	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	11200	usd
CY2022Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	11500	usd
CY2023Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	113353	usd
CY2023Q4	ONMT	Loan Extensions Current LoanExtensionsCurrent	2991679	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	253997	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	183683	usd
CY2023Q4	us-gaap	Loans Payable LoansPayable	38921	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	8490000	usd
CY2023Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	44673	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	120017	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	214850	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	69966	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1549820	usd
CY2023Q4	ONMT	Deferred Underwriter Fee Payable Current DeferredUnderwriterFeePayableCurrent	3525000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12833058	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11784569	usd
CY2022Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	1500000	usd
CY2022Q4	us-gaap	Unsecured Debt UnsecuredDebt	44144	usd
CY2022Q4	ONMT	Accrued Interest Related Party AccruedInterestRelatedParty	690772	usd
CY2023Q4	ONMT	Warrant Liability Non Current WarrantLiabilityNonCurrent	24582	usd
CY2022Q4	ONMT	Warrant Liability Non Current WarrantLiabilityNonCurrent	362558	usd
CY2022Q4	ONMT	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	4025000	usd
CY2022Q4	ONMT	Working Capital Loan WorkingCapitalLoan	207081	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	2545839	usd
CY2023Q4	us-gaap	Liabilities Liabilities	13322663	usd
CY2022Q4	us-gaap	Liabilities Liabilities	21159963	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23572232	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23572232	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4550166	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4550166	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2357	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6229639	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9274351	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9274351	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	455	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	28750110	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	42220714	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	24032561	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55082677	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43509964	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-12859606	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9274351	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463057	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30434314	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1021651	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1152738	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	1149551	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1513428	usd
CY2023	us-gaap	Gross Profit GrossProfit	-127900	usd
CY2022	us-gaap	Gross Profit GrossProfit	-360690	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5273503	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8755620	usd
CY2023	us-gaap	Other General Expense OtherGeneralExpense	226257	usd
CY2022	us-gaap	Other General Expense OtherGeneralExpense	398760	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1114977	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	957690	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1631613	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	952701	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	8246350	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	11064771	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8374250	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-11425461	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	10504327	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	214850	usd
CY2023	us-gaap	Interest Expense InterestExpense	749213	usd
CY2022	us-gaap	Interest Expense InterestExpense	403307	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	52256	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	46820	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-46822	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4489110	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	3572232	usd
CY2022	ONMT	Unrealized Gain Loss UnrealizedGainLoss	1371689	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14831206	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5195822	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23205456	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6229639	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.98
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.98
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23572232	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23572232	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14438035	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	200000	usd
CY2022Q4	us-gaap	Share Price SharePrice	1.00
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7500	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	2825960	usd
CY2022	ONMT	Common Stock Subject To Possible Redemption Value CommonStockSubjectToPossibleRedemptionValue	-3359591	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1392086	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1892741	usd
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7057092	usd
CY2023	ONMT	Stock Issued During Period Value Convertible Notes To Common Stock StockIssuedDuringPeriodValueConvertibleNotesToCommonStock	6177229	usd
CY2023	ONMT	Stock Issued During Period Value Stock Options To Common Stock StockIssuedDuringPeriodValueStockOptionsToCommonStock	612670	usd
CY2023	ONMT	Stock Issued During Period Value Converting Of Warrants To Common Stock StockIssuedDuringPeriodValueConvertingOfWarrantsToCommonStock	3859464	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-2257326	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	101071	usd
CY2023	ONMT	Stock Issued During Period Value Converting Data Knights Common Shares StockIssuedDuringPeriodValueConvertingDataKnightsCommonShares	633968	usd
CY2023	ONMT	Common Stock Subject To Possible Redemption Value CommonStockSubjectToPossibleRedemptionValue	-28750110	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	111957	usd
CY2023	ONMT	Retained Earnings Adjustment RetainedEarningsAdjustment	11632743	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23205456	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23205456	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-12859606	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-12859606	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-23205456	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6229639	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27983	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	24807	usd
CY2023	ONMT	Business Combination Cost BusinessCombinationCost	900152	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1599586	usd
CY2023	ONMT	Cash Held In Trust Account CashHeldInTrustAccount	29029416	usd
CY2022	ONMT	Cash Held In Trust Account CashHeldInTrustAccount	88291558	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	64594	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	875803	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1369825	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1929787	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	132665	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-72767	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	70314	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-458667	usd
CY2023	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-300	usd
CY2022	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	11500	usd
CY2023	ONMT	Increase Decrease In Exercise Tax Liability IncreaseDecreaseInExerciseTaxLiability	113353	usd
CY2023	ONMT	Increase Decrease In Extension Loan IncreaseDecreaseInExtensionLoan	445840	usd
CY2022	ONMT	Increase Decrease In Extension Loan IncreaseDecreaseInExtensionLoan	2545838	usd
CY2023	ONMT	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	-69966	usd
CY2022	ONMT	Increase Decrease Franchise Tax Payable IncreaseDecreaseFranchiseTaxPayable	-94043	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-94833	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	214850	usd
CY2023	ONMT	Increase Decrease In Working Capital Loan IncreaseDecreaseInWorkingCapitalLoan	-168159	usd
CY2022	ONMT	Increase Decrease In Working Capital Loan IncreaseDecreaseInWorkingCapitalLoan	207081	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	8220910	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	87239622	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43757	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	58137	usd
CY2022	ONMT	Proceeds From Issuance Of Common Stock One ProceedsFromIssuanceOfCommonStockOne	137	usd
CY2023	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	-10680772	usd
CY2022	us-gaap	Proceeds From Repayments Of Notes Payable ProceedsFromRepaymentsOfNotesPayable	5543162	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1549820	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	465024	usd
CY2023	ONMT	Proceeds From Business Loan ProceedsFromBusinessLoan	529	usd
CY2022	ONMT	Proceeds From Business Loan ProceedsFromBusinessLoan	-2754	usd
CY2023	ONMT	Proceeds From Common Stock Subject To Redemption ProceedsFromCommonStockSubjectToRedemption	-28750109	usd
CY2022	ONMT	Proceeds From Common Stock Subject To Redemption ProceedsFromCommonStockSubjectToRedemption	-88549890	usd
CY2023	ONMT	Proceeds From Deferred Underwriting Fee ProceedsFromDeferredUnderwritingFee	-500000	usd
CY2023	ONMT	Proceeds From Warrant Liability ProceedsFromWarrantLiability	337976	usd
CY2022	ONMT	Proceeds From Warrant Liability ProceedsFromWarrantLiability	4489110	usd
CY2023	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	18189350	usd
CY2022	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	2825823	usd
CY2023	ONMT	Proceeds From Issuance Of Common Stock Two ProceedsFromIssuanceOfCommonStockTwo	-59	usd
CY2023	ONMT	Class B Common Stock ClassBCommonStock	-425	usd
CY2023	ONMT	Procceds From Retained Earnings Adjustment ProccedsFromRetainedEarningsAdjustment	11632743	usd
CY2022	ONMT	Procceds From Retained Earnings Adjustment ProccedsFromRetainedEarningsAdjustment	-3359594	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-8431875	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-88032226	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-254722	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-850741	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	301730	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1152471	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	47008	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	301730	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zjt1UdiaaVH7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_869_zIt7XWTLer6d">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses, and the amounts disclosed in the related notes to the consolidated financial statements. Actual results and outcomes may differ materially from management’s estimates, judgments, and assumptions. Significant estimates, judgments, and assumptions used in these financial statements include, but are not limited to, those related to revenue, useful lives and realizability of long-lived assets, accounting for income taxes and related valuation allowances, and unit and stock-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts, and experience.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	102700	usd
CY2023	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2022	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6823785	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	6973587	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-55082677	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-43509964	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	282286	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	262992	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	183415	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	179895	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	98871	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	83097	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27983	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	24807	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1035947	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	481144	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	53268	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7859732	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	7507999	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7859732	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7507999	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	351734	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	1384220	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	690771	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	5140000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2056000	shares
CY2023	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock
CY2023	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	Series A-2 Preferred Stock and Series A-1 Preferred Stock convert 1-1 to commons stock
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1995000	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1995000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	25000	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1072816	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	947184	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	947184	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	577000	shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	7500	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	485684	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.00
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1031000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	567581	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.00
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	567581	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1031000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	947184	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y1M9D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	567581	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	723431	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M21D
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M7D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	692153	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	1.00
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	common stock equal to 10% of the number of shares of common stock of OneMedNet following the Business Combination for issuance thereunder
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	45584	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	47071	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	75987	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	174102	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.10
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.00
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1346288	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.00
CY2023Q4	us-gaap	Senior Notes Current SeniorNotesCurrent	1200000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	575	usd
CY2023	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7695	usd
CY2022	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	7694	usd

Files In Submission

Name	View Source	Status
0001493152-24-014092-index-headers.html	Edgar Link	pending
0001493152-24-014092-index.html	Edgar Link	pending
0001493152-24-014092.txt	Edgar Link	pending
0001493152-24-014092-xbrl.zip	Edgar Link	pending
ex10-4.htm	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex21.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-1_001.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
form10-k_002.jpg	Edgar Link	pending
form10-k_003.jpg	Edgar Link	pending
form10-k_004.jpg	Edgar Link	pending
form10-k_005.jpg	Edgar Link	pending
form10-k_006.jpg	Edgar Link	pending
form10-k_007.jpg	Edgar Link	pending
form10-k_008.jpg	Edgar Link	pending
form10-k_009.jpg	Edgar Link	pending
form10-k_010.jpg	Edgar Link	pending
form10-k_011.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
onmt-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
onmt-20231231_cal.xml	Edgar Link	unprocessable
onmt-20231231_def.xml	Edgar Link	unprocessable
onmt-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
onmt-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ONMD
OneMedNet Corp Stock $onmd

2024 Q2 Form 10-K Financial Statement

#000149315224014092 Filed on April 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONMD OneMedNet Corp Stock $onmd

2024 Q2 Form 10-K Financial Statement

#000149315224014092 Filed on April 09, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ONMD
OneMedNet Corp Stock $onmd